The subsets showing a reduction in DNAM-1 expression and an increase in TIGIT expressing cells are expanded in AML patients, supporting a shift in the balance to inhibition of lymphocyte function, limiting its ability to fight leukemia blasts. This evidence concerns the gene CD226 and acute myeloid leukemia.